A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone

Cecile Grootscholten, Jurgen W. C. Dieker, Fabian D. McGrath, Anja Roos, Ronald H. W. M. Derksen, Jakob van der Vlag, Mohamed R. Daha, Jo H. M. Berden*, null, null

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    62 Citaten (Scopus)


    Objective: To study the prevalence and course of anti-chromatin (anti-nucleosome, anti-double-stranded (ds) DNA and anti-histone) and anti-C1q autoantibodies in patients with proliferative lupus nephritis (LN), treated in a randomised controlled trial with either cyclophosphamide or azathioprine plus methylprednisolone.

    Methods: Autoantibody levels were measured and analysed in 52 patients with proliferative LN, during their first year of treatment. Levels in both treatment arms were compared and associations with clinical, serological and outcome parameters were studied.

    Results: At study entry, prevalences for anti-nucleosome, anti-dsDNA, anti-histone and anti-C1q autoantibodies were 81%, 96%, 23% and 65%, respectively. Anti-chromatin autoantibodies correlated with each other, but not with anti-C1q levels. If patients were divided for their autoantibody titre at the start of treatment above or below the median, the only significant differences were higher SLE disease activity index with higher anti-nucleosome, and higher creatinine with higher anti- C1q autoantibodies. During the first year, a comparable rapid decline in the levels of anti- nucleosome, anti- dsDNA and anti-C1q autoantibodies was seen in both treatment arms. Anti-histone autoantibody levels were low and did not change. Renal flares were not preceded by rises in autoantibody titres.

    Conclusions: These results indicate that measurement of antichromatin and anti-C1q autoantibodies is useful for diagnosing LN, but not for monitoring disease course.

    Originele taal-2English
    Pagina's (van-tot)693-696
    Aantal pagina's4
    TijdschriftAnnals of the Rheumatic Diseases
    Nummer van het tijdschrift5
    StatusPublished - 1-mei-2007

    Citeer dit